Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study

Anti‐programmed death‐1 (anti‐PD1) treatment has significantly improved outcomes of advanced melanoma with a considerable percentage of patients achieving complete response (CR). This real‐world study analyzed the feasibility of elective anti‐PD1 discontinuation in advanced melanoma patients with CR...

Full description

Saved in:
Bibliographic Details
Published in:Pigment cell and melanoma research Vol. 36; no. 5; pp. 388 - 398
Main Authors: Ochenduszko, Sebastian, García Sanchez, Javier, Fita, María José Juan, González‐Barrallo, Inés, Herrero Colomina, Julio, Mujika, Karmele, Beveridge, Roberto Diaz, Martínez, Silverio Ros, Lafuente, Blanca Sánchez, Tomas, Alberto Cunquero, Jaime, Alfonso Berrocal, Cerezuela Fuentes, Pablo, Fra, Pablo Luna, Peeters, Alicia Gervás, Meana García, José Andrés, García, María Asunción Algarra, Altozano, Javier Perez, Cancela, Maria, Puchades, Almudena Mateu, Roca, Francisco Ferrando, Maiques, Inmaculada Maestu
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-09-2023
Subjects:
Antibiotics
anti‐programmed death‐1
Cohort analysis
complete response
Feasibility studies
immunotherapy
Leukocytes (neutrophilic)
Liver diseases
Lymphocytes
Melanoma
Metastases
Observational studies
outcomes
PD-1 protein
Pembrolizumab
treatment discontinuation
complete response
melanoma
anti-programmed death-1
outcomes
treatment discontinuation
immunotherapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti‐programmed death‐1 (anti‐PD1) treatment has significantly improved outcomes of advanced melanoma with a considerable percentage of patients achieving complete response (CR). This real‐world study analyzed the feasibility of elective anti‐PD1 discontinuation in advanced melanoma patients with CR and evaluated factors related to sustained response. Thirty‐five patients with advanced cutaneous or primary unknown melanoma with CR to nivolumab or pembrolizumab from 11 centers were included. Mean age was 66.5 years, and 97.1% had ECOG PS 0–1. 28.6% had ≥3 metastatic sites with 58.8% having M1a‐M1b disease; 8.6% had liver and 5.7% had brain metastases. At baseline, 80% had normal LDH, and 85.7% had a neutrophil‐to‐lymphocyte ratio ≤3. 74.3% of patients had CR confirmed in PET‐CT. Median duration of anti‐PD1 was 23.4 months (range 1.3–50.5). 24 months after therapy discontinuation, 91.9% of patients were progression‐free. Estimated PFS and OS at 36, 48, and 60 months from the start of anti‐PD1 were 94.2%, 89.9%, 84.3%, and 97.1%, 93.3%, 93.3%, respectively. Antibiotics use after anti‐PD1 discontinuation increased the odds of progression (OR 16.53 [95% CI 1.7, 226.03]). The study confirms the feasibility of elective anti‐PD1 discontinuation in advanced melanoma patients with CR and favorable prognostic factors at baseline.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1755-1471
1755-148X
DOI:10.1111/pcmr.13093